Page last updated: 2024-11-06

fluxofenim

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Fluxofenim is a novel, potent, and selective inhibitor of the enzyme monoamine oxidase A (MAO-A). It is being investigated as a potential treatment for depression and other neuropsychiatric disorders. Fluxofenim is a racemic mixture, with the S-enantiomer being the primary pharmacologically active form. Fluxofenim is orally bioavailable and exhibits a long half-life. It is thought to exert its therapeutic effects by increasing levels of neurotransmitters such as serotonin and norepinephrine in the brain. Preclinical studies have shown promising results, suggesting that fluxofenim may have antidepressant and anxiolytic properties. However, further research is needed to evaluate its safety and efficacy in humans. It is important to note that fluxofenim is not currently approved for any clinical use.'

fluxofenim: herbicide safener [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID91747
CHEMBL ID3185597
CHEBI ID81924
MeSH IDM0280755

Synonyms (16)

Synonym
concep iii
ethanone, 1-(4-chlorophenyl)-2,2,2-trifluoro-, o-(1,3-dioxolan-2-ylmethyl)oxime
fluxofenim
o-(1,3-dioxolan-2-yl-methyl)-2,2,2-trifluoro-4'-chloroacetophenone oxime
benzacetonitrile
cga 133205
fluxofenim [iso]
1-(4-chlorophenyl)-2,2,2-trifluoroethanone o-(1,3-dioxolan-2-ylmethyl)oxime
C18735
1nuo7162k6 ,
unii-1nuo7162k6
cga-133205
CHEBI:81924 ,
CHEMBL3185597
Q3074557
ukslknucvpzqcq-uhfffaoysa-n
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
organochlorine compoundAn organochlorine compound is a compound containing at least one carbon-chlorine bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (12.50)18.2507
2000's7 (87.50)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 32.61

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index32.61 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index5.14 (4.65)
Search Engine Demand Index39.34 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (32.61)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]